Prospective Observational Study To Identify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) And ALK Translocation And To Establish Their Therapeutic Management (IDEALK)

- Patients with Advanced or metastatic non-small cell lung cancer

- Patients who will be screened for anaplastic lymphoma kinase (ALK) rearrangement

- Age > 18 years

- For the patients that will be recruited prospectively: Patients must have a signed
informed consent document.

- For the treatment sub-study, patients must also meet the following criteria

- Confirmed anaplastic lymphoma kinase (ALK)-positive tumour

- Patients treated with crizotinib under routine clinical practice

- Patients with a minimum data registered at the medical history